510(k) SUMMARY

DENSPLY

NAME & ADDRESS:

DENTSPLY International 570 West College Avenue

P.O. Box 872 York, PA 17405-0872 (717) 845-7511

Fax (717) 849-4762 www.dentsply.com

OCT - 1 2003

P. J. Lehn Telefax (717) 849-4343

CONTACT:

P. Jeffery Lehn

DATE PREPARED:

July 25, 2003

TRADE OR PROPRIETARY NAME:

APOLLO 3 ALLOY

CLASSIFICATION NAME:

Gold-based alloy for clinical use (872.3060)

PREDICATE DEVICES:

Degulor M Alloy K951779

DEVICE DESCRIPTION: APOLLO 3 ALLOY is a yellow, high noble, gold-based dental alloy.

INTENDED USE: APOLLO 3 ALLOY is indicated as a dental alloy for fabricating inlays, crowns and small span bridges.

TECHNOLOGICAL CHARACTERISTICS: All of the components found in APOLLO 3 ALLOY have been used in legally marketed devices.

APOLLO 3 ALLOY is very similar in formulation to legally marketed dental alloys. This alloy has been on the European market since 1978 with over 2 million units placed. APOLLO 3 ALLOY was tested for Cytotoxicity and AMES mutagenicity and found to be non-cytotoxic and non-mutagenic. Therefore, it was determined that no further biocompatibility testing was necessary

We believe that the prior use of the components of APOLLO 3 ALLOY in legally marketed devices, the performance data provided, the biocompatibility test results, and the historical use of the device in Europe support the safety and effectiveness of APOLLO 3 ALLOY for the indicated uses.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT - 1 2003

Mr. P Jeffery Lehn
Director of Corporate Compliance and Regulatory Affairs
Dentsply International
570 West College Avenue
P.O. Box 872
York, Pennsylvania 17405-0872

Re: K032320

Trade/Device Name: Apollo 3 Alloy Regulation Number: 872.3060

Regulation Name: Gold-Based Alloys and Precious Metal Alloys for Clinical Use

Regulatory Class: II Product Code: EJT Dated: July 25, 2003 Received: July 28, 2003

Dear Mr. Lehn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Susan Runner, DDS, MA

Interim Director

Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

(As Required by 21 CFR 807.87(e)

510(K) Number (if k	nown):	
Device Name:	APOLLO 3 ALLO	\underline{OY}
Indications for Use:		
(Division Division Infection	owns and small span	KPM
PLEASE DO NOT WRITI	E BELOW THIS LIN	E—CONTINUE ON ANOTHER PAGE IF NEEDED
Conc	urrence of CDRH, Of	fice of Device Evaluation (ODE)
Prescription Use(Per 21 CFR 80)		Over-The-Counter Use (Optional Format 1-2-96)